ZBIO

Zenas BioPharma, Inc. Common Stock

11.58 USD
+0.38
3.39%
At close Apr 30, 4:00 PM EDT
After hours
11.58
+0.00
0.00%
1 day
3.39%
5 days
18.53%
1 month
46.58%
3 months
51.97%
6 months
-44.86%
Year to date
28.52%
1 year
-36.20%
5 years
-36.20%
10 years
-36.20%
 

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

49% more funds holding

Funds holding: 43 [Q3] → 64 (+21) [Q4]

13.78% more ownership

Funds ownership: 62.07% [Q3] → 75.85% (+13.78%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

38% less capital invested

Capital invested by funds: $417M [Q3] → $260M (-$158M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$19
64%
upside
Avg. target
$32
178%
upside
High target
$45
289%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Martin Fan
50% 1-year accuracy
1 / 2 met price target
202%upside
$35
Outperform
Initiated
20 Mar 2025
Guggenheim
Yatin Suneja
24% 1-year accuracy
8 / 33 met price target
289%upside
$45
Buy
Reiterated
12 Mar 2025
HC Wainwright & Co.
Matthew Caufield
25% 1-year accuracy
17 / 67 met price target
159%upside
$30
Buy
Reiterated
12 Mar 2025
Wolfe Research
Andy Chen
53% 1-year accuracy
8 / 15 met price target
64%upside
$19
Outperform
Initiated
4 Feb 2025

Financial journalist opinion

Based on 158 articles about ZBIO published over the past 30 days

Neutral
Accesswire
7 hours ago
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146313&wire=1 or contact Joseph E. Levi, Esq.
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO
Neutral
Accesswire
12 hours ago
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146272&wire=1 or contact Joseph E. Levi, Esq.
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
Neutral
GlobeNewsWire
12 hours ago
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO) and certain of its officers.
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Neutral
Accesswire
17 hours ago
June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZBIO
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146234&wire=1 or contact Joseph E. Levi, Esq.
June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZBIO
Neutral
Accesswire
18 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Neutral
Accesswire
21 hours ago
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146132&wire=1 or contact Joseph E. Levi, Esq.
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Neutral
Accesswire
21 hours ago
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Neutral
Accesswire
1 day ago
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146094&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
Neutral
GlobeNewsWire
1 day ago
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class Action
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class Action
Neutral
Accesswire
1 day ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 16, 2025 in Zenas BioPharma, Inc. Lawsuit - ZBIO
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=146089&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 16, 2025 in Zenas BioPharma, Inc. Lawsuit - ZBIO
Charts implemented using Lightweight Charts™